Imbruvica ibrutinib regulatory update

AbbVie submitted an sNDA to FDA for Imbruvica ibrutinib for first-line treatment of chronic lymphocytic leukemia (CLL). The sNDA is based on data from the Phase III RESONATE-2 (PCYC-1115) trial (see B...